pharmaphorum1h
MSD joins PD-1/VEGF push in cancer with LaNova deal
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Merck to Participate in the Jefferies London Healthcare Conference
About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the ...
Le Lézard2h
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Merck , known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an ...
Daily7h
Ginkgo Bioworks advances collaboration with Merck to improve Biologics manufacturing
Boston: Ginkgo Bioworks has announced the completion of the first milestone of a previously announced partnership with Merck, ...
Pharmabiz9h
Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million
Ginkgo Bioworks advances collaboration with Merck to improve biologics manufacturing; Ginkgo to receive a research milestone payment of $9 million: Boston, Massachusetts Thursday, ...
Kimberly-Clark Elects Joseph Romanelli to its Board of Directors
Kimberly-Clark Corporation (NYSE: KMB) today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of ...